PTPN11 inhibitors
The present invention relates to compounds which are useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
1. A compound, represented by the formula:
2. A pharmaceutically acceptable salt of a compound, wherein the compound is represented by the formula:
3. A pharmaceutical composition comprising the compound of claim 1 , together with a pharmaceutically acceptable carrier.
4. A pharmaceutical composition comprising a pharmaceutically acceptable salt of the compound of claim 2 , together with a pharmaceutically acceptable carrier.
5. A method of treatment of a PTPN11-mediated disease comprising administering a therapeutically effective amount of the compound of claim 1 , to a patient in need thereof, wherein the PTPN11-mediated disease is cancer selected from the group consisting of breast cancer, colon cancer, lung cancer, esophageal cancer, gastric cancer, leukemia, and melanoma.
6. A method of treatment of a PTPN11-mediated disease comprising administering a therapeutically effective amount of a pharmaceutically acceptable salt of the compound of claim 1 , to a patient in need thereof, wherein the PTPN11-mediated disease is cancer selected from the group consisting of breast cancer, colon cancer, lung cancer, esophageal cancer, gastric cancer, leukemia, and melanoma.
7. A compound, represented by the formula:
8. A pharmaceutically acceptable salt of a compound, wherein the compound is represented by the formula:
9. A pharmaceutical composition comprising the compound of claim 7 , together with a pharmaceutically acceptable carrier.
10. A pharmaceutical composition comprising a pharmaceutically acceptable salt of the compound of claim 8 , together with a pharmaceutically acceptable carrier.
11. A method of treatment of a PTPN11-mediated disease comprising administering a therapeutically effective amount of the compound of claim 7 , to a patient in need thereof, wherein the PTPN11-mediated disease is cancer selected from the group consisting of breast cancer, colon cancer, lung cancer, esophageal cancer, gastric cancer, leukemia, and melanoma.
12. A method of treatment of a PTPN11-mediated disease comprising administering a therapeutically effective amount of a pharmaceutically acceptable salt of the compound of claim 8 , to a patient in need thereof, wherein the PTPN11-mediated disease is cancer selected from the group consisting of breast cancer, colon cancer, lung cancer, esophageal cancer, gastric cancer, leukemia, and melanoma.
13. A method of treatment of lung cancer comprising administering to a patient in need thereof a therapeutically effective amount of the compound represented by the formula:
or a pharmaceutically acceptable salt thereof.
14. The method of claim 13 , wherein the lung cancer is non-small cell lung cancer.
15. A method of treatment of colon cancer comprising administering to a patient in need thereof a therapeutically effective amount of the compound represented by the formula:
or a pharmaceutically acceptable salt thereof.
16. The method of claim 15 , wherein the colon cancer is colorectal cancer.